Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

OBJECTIVE: To evaluate the impact of two calcitonin gene–related peptide (CGRP)‐targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on the pharmacokinetic (PK) profile, safety, and tolerability of ubrogepant. BACKGROUND: People taking CGRP‐targeted mAbs for migraine prevention sometime...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakate, Abhijeet, Blumenfeld, Andrew M., Boinpally, Ramesh, Butler, Matthew, Borbridge, Lisa, Contreras‐De Lama, Janette, McGeeney, Danielle, Periclou, Antonia, Lipton, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252052/
https://www.ncbi.nlm.nih.gov/pubmed/33818780
http://dx.doi.org/10.1111/head.14095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252052/
https://www.ncbi.nlm.nih.gov/pubmed/33818780
http://dx.doi.org/10.1111/head.14095

Ejemplares similares